Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Comparison of fibrin adhesives prepared by 3 different methods.

Cavichiolo JB, Buschle M, Carvalho B.

Int Arch Otorhinolaryngol. 2013 Jan;17(1):62-5. doi: 10.7162/S1809-97772013000100011.

2.

Cochlear implant in the treatment of incapacitating unilateral tinnitus: case report.

Mendes Rde C, Ribas A, de Macedo IP, Buschle M, Ataíde AL, Pereira R, Kochen AP.

Int Tinnitus J. 2012;17(2):200-4. doi: 10.5935/0946-5448.20120035.

PMID:
24333895
3.

Bilateral narrow duplication of the internal auditory canal.

Coelho LO, Ono SE, Neto AC, Polanski JF, Buschle M.

J Laryngol Otol. 2010 Sep;124(9):1003-6. doi: 10.1017/S0022215110000666. Epub 2010 Apr 29.

PMID:
20426887
4.

Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals.

Schalich J, Vytvytska O, Zauner W, Fischer MB, Buschle M, Aichinger G, Klade CS.

Biol Chem. 2008 May;389(5):551-9.

PMID:
18953722
5.

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP.

Gastroenterology. 2008 May;134(5):1385-95. doi: 10.1053/j.gastro.2008.02.058. Epub 2008 Mar 4.

PMID:
18471515
6.

Stapes surgery in residency: the UFPR clinical hospital experience.

Caldart AU, Terruel I, Enge DJ Jr, Kurogi AS, Buschle M, Mocellin M.

Braz J Otorhinolaryngol. 2007 Sep-Oct;73(5):647-53.

7.

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses.

Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, von Gabain A, Buschle M, Lingnau K.

Vaccine. 2006 Jun 29;24(26):5461-72. Epub 2006 Apr 7.

PMID:
16678312
8.

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS.

Vaccine. 2006 May 15;24(20):4343-53. Epub 2006 Mar 20.

PMID:
16581161
9.

The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens.

Fritz JH, Brunner S, Birnstiel ML, Buschle M, Gabain Av, Mattner F, Zauner W.

Vaccine. 2004 Sep 3;22(25-26):3274-84.

PMID:
15308350
10.

PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.

Lachmann M, Gelbmann D, Kálmán E, Polgár B, Buschle M, Von Gabain A, Szekeres-Barthó J, Nagy E.

Int J Cancer. 2004 Oct 20;112(1):51-60.

11.

Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens.

Henics T, Winkler B, Pfeifer U, Gill SR, Buschle M, von Gabain A, Meinke AL.

Biotechniques. 2003 Jul;35(1):196-202, 204, 206 passim.

12.

The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria.

Bruna-Romero O, Schmieg J, Del Val M, Buschle M, Tsuji M.

J Immunol. 2003 Mar 15;170(6):3195-203.

13.

Retrovirus-mediated IL-7 expression in leukemic dendritic cells generated from primary acute myelogenous leukemias enhances their functional properties.

Bello-Fernández C, Stasakova J, Renner A, Carballido-Perrig N, Koening M, Waclavicek M, Madjic O, Oehler L, Haas O, Carballido JM, Buschle M, Knapp W.

Blood. 2003 Mar 15;101(6):2184-90. Epub 2002 Nov 7.

PMID:
12424204
14.

Induction of specific immune responses by polycation-based vaccines.

Lührs P, Schmidt W, Kutil R, Buschle M, Wagner SN, Stingl G, Schneeberger A.

J Immunol. 2002 Nov 1;169(9):5217-26.

15.

Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration.

Marschütz MK, Zauner W, Mattner F, Otava A, Buschle M, Bernkop-Schnürch A.

Peptides. 2002 Oct;23(10):1727-33.

PMID:
12383859
17.
18.

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.

Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Söllner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Nagy E, Meinke A.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6573-8. Epub 2002 May 7.

19.

Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.

Mattner F, Fleitmann JK, Lingnau K, Schmidt W, Egyed A, Fritz J, Zauner W, Wittmann B, Gorny I, Berger M, Kirlappos H, Otava A, Birnstiel ML, Buschle M.

Cancer Res. 2002 Mar 1;62(5):1477-80.

20.

Defined synthetic vaccines.

Zauner W, Lingnau K, Mattner F, von Gabain A, Buschle M.

Biol Chem. 2001 Apr;382(4):581-95. Review.

PMID:
11405222
21.

Vaccine development: from empirical medicine to molecularly designed therapy.

Buschle M, Mattner F, Zauner W, von Gabain A.

Biol Chem. 2001 Apr;382(4):505. No abstract available.

PMID:
11405215
22.

Modified technique of delivering solutions to rat coronary arteries in the transplant setting.

Nourani F, Laufer G, Hollensteiner H, Bergmeister H, Buschle M, Khazen C, Ankersmit J, Traxler H, Wolner E, Losert U, Kocher AA.

Transplant Proc. 1999 Dec;31(8):3255-6. No abstract available.

PMID:
10616466
23.
24.

Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.

Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Bröcker EB, Wolff K, Stingl G.

Hum Gene Ther. 1999 Apr 10;10(6):983-93.

PMID:
10223732
25.

Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET).

Schmidt W, Maass G, Buschle M, Schweighoffer T, Berger M, Herbst E, Schilcher F, Birnstiel ML.

Gene. 1997 Apr 29;190(1):211-6.

PMID:
9185869
26.

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.

Stingl G, Bröcker EB, Mertelsmann R, Wolff K, Schreiber S, Kämpgen E, Schneeberger A, Trcka J, Brennscheidt U, Veelken H, Birnstiel ML, Zatloukal K, Maass G, Wagner E, Buschle M, Kempe ER, Weber HA, Voigt T.

J Mol Med (Berl). 1997 Apr;75(4):297-9. No abstract available.

PMID:
9151216
27.

Cell-free tumor antigen peptide-based cancer vaccines.

Schmidt W, Buschle M, Zauner W, Kirlappos H, Mechtler K, Trska B, Birnstiel ML.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3262-7.

28.

Transloading of tumor antigen-derived peptides into antigen-presenting cells.

Buschle M, Schmidt W, Zauner W, Mechtler K, Trska B, Kirlappos H, Birnstiel ML.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3256-61.

29.

Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines.

Schmidt W, Steinlein P, Buschle M, Schweighoffer T, Herbst E, Mechtler K, Kirlappos H, Birnstiel ML.

Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9759-63.

30.

Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines.

Schweighoffer T, Berger M, Buschle M, Schmidt W, Birnstiel ML.

Cytokines Mol Ther. 1996 Sep;2(3):185-91. Review.

PMID:
9384703
31.
32.

Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex.

Buschle M, Cotten M, Kirlappos H, Mechtler K, Schaffner G, Zauner W, Birnstiel ML, Wagner E.

Hum Gene Ther. 1995 Jun;6(6):753-61.

PMID:
7548275
33.

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.

Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, et al.

J Immunol. 1995 Apr 1;154(7):3406-19.

PMID:
7897222
34.

Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo.

Maass G, Schweighoffer T, Berger M, Schmidt W, Herbst E, Zatloukal K, Buschle M, Birnstiel ML.

Int J Immunopharmacol. 1995 Feb;17(2):65-73.

PMID:
7657408
35.
36.

Genetic modification of cells by receptor-mediated adenovirus-augmented gene delivery: a new approach for immunotherapy of cancer.

Zatloukal K, Schneeberger A, Berger M, Koszik F, Schmidt W, Wagner E, Cotten M, Buschle M, Maass G, Stingl G, et al.

Verh Dtsch Ges Pathol. 1994;78:171-6.

PMID:
7533981
37.

Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients.

Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN.

Lancet. 1993 Nov 6;342(8880):1134-7.

PMID:
7901474
38.

Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein.

Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Aricò M, Biondi A, Pui CH.

Blood. 1993 Feb 15;81(4):1025-31.

PMID:
8427984
39.

Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.

Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK.

J Exp Med. 1993 Jan 1;177(1):213-8.

40.

An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer.

Rill DR, Moen RC, Buschle M, Bartholomew C, Foreman NK, Mirro J Jr, Krance RA, Ihle JN, Brenner MK.

Blood. 1992 May 15;79(10):2694-700.

PMID:
1316784
41.

Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation.

Rill DR, Buschle M, Foreman NK, Bartholomew C, Moen RC, Santana VM, Ihle JN, Brenner MK.

Hum Gene Ther. 1992 Apr;3(2):129-36.

PMID:
1391032
42.

Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.

Rooney CM, Brimmell M, Buschle M, Allan G, Farrell PJ, Kolman JL.

J Virol. 1992 Jan;66(1):496-504.

43.

Transfection and gene expression in normal and malignant primary B lymphocytes.

Buschle M, Brenner MK, Chen IS, Drexler HG, Gignac SM, Rooney CM.

J Immunol Methods. 1990 Oct 4;133(1):77-85.

PMID:
1698880
44.

Down-regulation of CD5 mRNA in B-chronic lymphocytic leukemia cells by differentiation-inducing agents.

Gignac SM, Buschle M, Hoffbrand AV, Drexler HG.

Eur J Immunol. 1990 May;20(5):1119-23.

PMID:
1694132
45.

Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor.

Gignac SM, Buschle M, Heslop HE, Brenner MK, Hoffbrand AV, Drexler HG.

Leuk Lymphoma. 1990;3(1):37-43. doi: 10.3109/10428199009050973.

PMID:
27457196
46.

Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.

Gignac SM, Buschle M, Roberts RM, Pettit GR, Hoffbrand AV, Drexler HG.

Leuk Lymphoma. 1990;3(1):19-29. doi: 10.3109/10428199009050971.

PMID:
27457194
47.

Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci.

Bartram CR, Ludwig WD, Hiddemann W, Lyons J, Buschle M, Ritter J, Harbott J, Fröhlich A, Janssen JW.

Leukemia. 1989 Apr;3(4):247-56.

PMID:
2564452
48.

ras gene mutations and clonal analysis using RFLPs of X-chromosome genes in myelodysplastic syndromes.

Janssen JW, Buschle M, Layton M, Lyons J, Bartram CR.

Haematol Blood Transfus. 1989;32:386-9. No abstract available.

PMID:
2576237
49.

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

Janssen JW, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H, Heimpel H, Kubanek B, Kleihauer E, Mufti GJ, et al.

Blood. 1989 Jan;73(1):248-54.

PMID:
2562924
50.

Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation.

Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR.

Leukemia. 1988 Oct;2(10):658-60.

PMID:
3050294

Supplemental Content

Loading ...
Support Center